No Data
No Data
Aodong Medicine Industry's Unit Gets Nod to Register 10 Chinese Traditional Medicines
Jilin Aodong Medicine Industry Group's (SHE:000623) subsidiary, Jilin Aodong Yanbian Pharmaceutical, received registration certificates for 10 Chinese traditional medicines from drug regulator Nationa
Jilin Aodong Pharmaceutical Group (000623.SZ): Sales revenue of 8 individual products exceeding 10 million yuan in 2023.
On July 4th, Gelunhui reported that Jilin Aodong Pharmaceutical Group (000623.SZ) stated at an investor relations event that the company invests in and establishes two subsidiaries in the field of big health, namely health technology and enzyme technology. In 2023, the company achieved sales revenue of 363.2839 million yuan in the field of big health, an increase of 3.9648 million yuan compared to the same period of the previous year, a year-on-year increase of 1.10%. In 2023, the company produced and sold more than 200 kinds of health products such as health functional foods and dietary supplements, including 22 certificates for registered health foods and 76 certificates for filed health foods. The main product is "Gu Bi Li Amino Sugar Chondroitin Hyaluronic Acid Tablets".
Jilin Aodong Pharmaceutical Group (000623.SZ): its subsidiary obtained 10 Traditional Chinese Medicine formula granules listing approval documents.
On July 2, Ge Long Hui reported that Jilin Aodong (000623.SZ) announced that its holding subsidiary, Yanbian Aodong Pharmacy Co., Ltd. (hereinafter referred to as "Yanbian Pharmacy"), has obtained 10 registration certificates for the listing of traditional Chinese medicine formula granules, including Nan Wuweizi formula granules, vinegar Nan Wuweizi formula granules, and Bu Zha Ye formula granules. Yanbian Pharmacy, as a core enterprise of the company, has certain advantages in the field of traditional Chinese medicine and has accumulated 451 registration certificates for the listing of traditional Chinese medicine formula granules as of the date of this announcement. This is of great significance for the company to expand its business in traditional Chinese medicine formula granules and continues to promote the company's business.
Jilin Aodong Pharmaceutical Group (000623.SZ) equity distribution in 2023: 6 yuan per 10 shares.
Jilin Aodong Pharmaceutical Group (000623.SZ) has announced that the company's equity distribution plan for 2023 will be based on the current...
Jilin Aodong Pharmaceutical Group Co., Ltd.'s (SZSE:000623) Stock Price Dropped 4.3% Last Week; Retail Investors Would Not Be Happy
Key Insights Significant control over Jilin Aodong Pharmaceutical Group by retail investors implies that the general public has more power to influence management and governance-related decisions A
Jilin Aodong Pharmaceuticals (000623.SZ): Yanbian Pharmaceutical obtained 20 traditional chinese medicine formula particle listing record certificates.
On June 25th, Gelonhui reported that Jilin Aodong (000623.SZ) announced that its subsidiary, Jilin Aodong Yanbian Pharmaceutical Co., Ltd. (referred to as "Yanbian Pharmaceutical"), a controlled subsidiary of Jilin Aodong Pharmaceutical Group Co., Ltd., has obtained 20 Certificates of Registration for Listed Traditional Chinese Medicine Particle Formulas.
No Data